EGFR and non-small cell lung carcinoma: Consequently, the therapeutic strategy for advanced NSCLC patients harboring EGFR-positive mutations has transitioned from chemotherapy to tyrosine kinase inhibitors (TKIs), leading to a notable enhancement in patient survival time and quality of life (Mitsudomi et al., 2010; Rosell et al., 2012).